ATE382054T1 - Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis - Google Patents

Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Info

Publication number
ATE382054T1
ATE382054T1 AT02739051T AT02739051T ATE382054T1 AT E382054 T1 ATE382054 T1 AT E382054T1 AT 02739051 T AT02739051 T AT 02739051T AT 02739051 T AT02739051 T AT 02739051T AT E382054 T1 ATE382054 T1 AT E382054T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
eustasis
oxytocin
aciding
preparing
Prior art date
Application number
AT02739051T
Other languages
English (en)
Inventor
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Maria Petersson
Original Assignee
Kerstin Uvnaes-Moberg
Thomas Lundeberg
Maria Petersson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kerstin Uvnaes-Moberg, Thomas Lundeberg, Maria Petersson filed Critical Kerstin Uvnaes-Moberg
Application granted granted Critical
Publication of ATE382054T1 publication Critical patent/ATE382054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02739051T 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis ATE382054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102184A SE0102184D0 (sv) 2001-06-19 2001-06-19 New subject-matter

Publications (1)

Publication Number Publication Date
ATE382054T1 true ATE382054T1 (de) 2008-01-15

Family

ID=20284539

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739051T ATE382054T1 (de) 2001-06-19 2002-06-19 Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Country Status (6)

Country Link
US (1) US7714105B2 (de)
EP (1) EP1409518B1 (de)
AT (1) ATE382054T1 (de)
DE (1) DE60224280D1 (de)
SE (1) SE0102184D0 (de)
WO (1) WO2002102832A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4654418B2 (ja) * 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
FR2954167A1 (fr) 2009-09-04 2011-06-24 Centre Nat Rech Scient Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
SE536091C2 (sv) 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
JP6527996B2 (ja) * 2017-09-12 2019-06-12 株式会社 金冠堂 Ｆｇｆ活性に影響を与えるジペプチド

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) * 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
EP0146113A3 (de) * 1983-12-15 1987-08-19 Dieter Aderhold Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut
US5767083A (en) * 1994-05-04 1998-06-16 Innapharma, Inc. Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent
SE9803271D0 (sv) * 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for well-being

Also Published As

Publication number Publication date
US7714105B2 (en) 2010-05-11
WO2002102832A1 (en) 2002-12-27
EP1409518A1 (de) 2004-04-21
EP1409518B1 (de) 2007-12-26
DE60224280D1 (de) 2008-02-07
SE0102184D0 (sv) 2001-06-19
US20040259805A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
BR0012243A (pt) Triflúor butenos nematocidas
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DE602004023725D1 (de) Muteine von tränen-lipocalin
DE60225666D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
DE60222644D1 (de) Prozess zur herstellung von transparenten formteilen
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
DE60318831D1 (de) System zur abgabe von anästhetika
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE60129518D1 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
GB0110430D0 (en) Protein variants and uses thereof
ATE343605T1 (de) Zusammensetzungen zur herstellung von aminoplasterzeugnissen
PT1290160E (pt) Polipeptideos pellino humanos
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE60328456D1 (de) Eine kontinuierliche zellinie zur herstellung von impfstoffen
MXPA05007901A (es) Terapia de combinacion para hcv.
ATE499383T1 (de) Eine methode zur herstellung von menschlichem natürlichem interferon-alpha
BR9812869A (pt) Processo para a preparação de benzofuranonas eventualmente substituìdas
DE60216090D1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties